UNSPSC 51172180: Propiverine hydrochloride

This classification denotes an antispasmotic agent and antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DC4GZD10H3. European Medicines Agency schedules Propiverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04087MIG. Propiverine hydrochloride generally arises in the molecular formula C23H29NO3.CLH. The term 'propiverine hydrochloride' is a Japanese Accepted Name designation.

Most nations, for tariff and trade purposes, schedule propiverine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, PROPIVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCOC(C1CCCCC1)(C2CCCCC2)C(=O)OC3CCN(CC3)C.CL.

UNSPSC 51172180 Propiverine hydrochloride, a Commodity code, represents pharmaceutical products that state and local governments procure through specimen collection vendors, cooperative purchasing alliances, and pharmacy benefit programs. The recent opportunities show state and local buyers sourcing drug-testing pharmaceuticals and screening reagents for offender supervision programs, generic multi-source pharmaceuticals through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels. The issuing bodies include county community supervision departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across state and local government jurisdictions.

Activity appears concentrated in Texas and Minnesota, with a Texas county (Collin County Community Supervision and Corrections Department) soliciting offender specimen collection and drug testing services via RFP 2026-327, due July 23, 2026, valued at approximately $600,000 over two years with three optional one-year renewals, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issuing an RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, to supply participating state and local government facilities across multiple states including Oregon. The Texas Health and Human Services Commission issued an exploratory RFI in April 2026 regarding direct-to-manufacturer prescription programs, signaling potential future procurement activity in pharmaceutical supply chains outside conventional distribution arrangements. Testing demand in the Collin County opportunity is approximately 25,031 tests annually, with five- and six-panel screening configurations and confirmation testing via LC/MS/MS or GC/MS, and successful vendors must maintain SAMHSA, Texas DPS, or CAP laboratory certification. The MMCAP RFP requires vendors to supply products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with pricing effective July 1, 2026, and imposes a 3 percent administrative fee plus performance penalties up to $1,500 per violation.